>Cell Genesys' current business strategy is to seek a licensing partner for
>its Parkinson's disease gene therapy program.
Treating Parkinson's is big business and like it or not, the major
Parkinson's organizations are mostly funded by the pharmaceutical industry.
If a nose spray with the AAV vectors could cure Parkinson's, isn't it
conceivable that a drug company would buy the technology and rights and
"study" it to death quietly. Since they would own the rights, they could
keep it off the market and it would never get to the FDA.
The drug industry fears a cure for Parkinson's. Two to three thousands of
dollars per year times a million patients would be a big loss. Startup
companies like Genesys don't have the funds to take this idea through trials.
What are the possible solutions?
[log in to unmask] Search the parkinsn archive online at:
http://james.parkinsons.org.uk
Catch the Parkinsn List messages on line at:
http://www.ionet.net/~jcott/homepage/archive/patp.html
*NEW*Click the page ads and use the new search tools*NEW*
John Cottingham
